Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 105,109 | 173,063 | 125,989 | 220,797 | 132,262 |
| Marketable Securities | 91,857 | 64,698 | 124,659 | 21,106 | 32,606 |
| Receivables | 19,638 | 20,302 | 22,802 | 17,415 | 14,158 |
| Inventories | 7,590 | 9,227 | 7,594 | 7,442 | 7,243 |
| TOTAL | $237,177 | $276,135 | $295,097 | $278,968 | $196,760 |
| Non-Current Assets | |||||
| PPE Net | 627 | 655 | 608 | 580 | 566 |
| Investments And Advances | 4,514 | 5,022 | 4,641 | 203 | 481 |
| Other Non-Current Assets | 5,300 | 3,899 | 1,597 | 2,098 | 2,767 |
| TOTAL | $10,441 | $9,576 | $6,846 | $2,881 | $3,814 |
| Total Assets | $247,618 | $285,711 | $301,943 | $281,849 | $200,574 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 30,322 | 27,431 | 19,685 | 23,754 | 18,158 |
| Accrued Expenses | 6,967 | 10,570 | 9,029 | 6,849 | 4,985 |
| Other current liabilities | 4,711 | 7,948 | 4,073 | 3,620 | 3,197 |
| TOTAL | $42,000 | $45,949 | $32,787 | $34,223 | $26,340 |
| Non-Current Liabilities | |||||
| Long Term Debt | 122,108 | 121,734 | 121,709 | 97,813 | 97,590 |
| Other Non-Current Liabilities | 129,968 | 126,831 | 121,932 | 119,499 | 116,778 |
| TOTAL | $252,076 | $248,565 | $243,641 | $217,312 | $214,368 |
| Total Liabilities | $294,076 | $294,514 | $276,428 | $251,535 | $240,708 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 46,107 | 46,094 | 42,199 | 42,114 | 36,130 |
| Common Shares | 126 | 115 | 115 | 112 | 99 |
| Retained earnings | -850,065 | -806,222 | -768,710 | -745,037 | -711,634 |
| Other shareholders' equity | 14 | 56 | 236 | -31 | -37 |
| TOTAL | $-46,458 | $-8,803 | $25,515 | $30,314 | $-40,134 |
| Total Liabilities And Equity | $247,618 | $285,711 | $301,943 | $281,849 | $200,574 |